COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
dc.contributor.author | Maisonnasse, Pauline | |
dc.contributor.author | Aldon, Yoann | |
dc.contributor.author | Marc, Aurélien | |
dc.contributor.author | Marlin, Romain | |
dc.contributor.author | Dereuddre-Bosquet, Nathalie | |
dc.contributor.author | Kuzmina, Natalia A | |
dc.contributor.author | Freyn, Alec W | |
dc.contributor.author | Snitselaar, Jonne L | |
dc.contributor.author | Gonçalves, Antonio | |
dc.contributor.author | Caniels, Tom G | |
dc.contributor.author | Burger, Judith A | |
dc.contributor.author | Poniman, Meliawati | |
dc.contributor.author | Bontjer, Ilja | |
dc.contributor.author | Chesnais, Virginie | |
dc.contributor.author | Diry, Ségolène | |
dc.contributor.author | Iershov, Anton | |
dc.contributor.author | Ronk, Adam J | |
dc.contributor.author | Jangra, Sonia | |
dc.contributor.author | Rathnasinghe, Raveen | |
dc.contributor.author | Brouwer, Philip J M | |
dc.contributor.author | Bijl, Tom P L | |
dc.contributor.author | van Schooten, Jelle | |
dc.contributor.author | Brinkkemper, Mitch | |
dc.contributor.author | Liu, Hejun | |
dc.contributor.author | Yuan, Meng | |
dc.contributor.author | Mire, Chad E | |
dc.contributor.author | van Breemen, Mariëlle J | |
dc.contributor.author | Contreras, Vanessa | |
dc.contributor.author | Naninck, Thibaut | |
dc.contributor.author | Lemaître, Julien | |
dc.contributor.author | Kahlaoui, Nidhal | |
dc.contributor.author | Relouzat, Francis | |
dc.contributor.author | Chapon, Catherine | |
dc.contributor.author | Ho Tsong Fang, Raphaël | |
dc.contributor.author | McDanal, Charlene | |
dc.contributor.author | Osei-Twum, Mary | |
dc.contributor.author | St-Amant, Natalie | |
dc.contributor.author | Gagnon, Luc | |
dc.contributor.author | Montefiori, David C | |
dc.contributor.author | Wilson, Ian A | |
dc.contributor.author | Ginoux, Eric | |
dc.contributor.author | de Bree, Godelieve J | |
dc.contributor.author | García-Sastre, Adolfo | |
dc.contributor.author | Schotsaert, Michael | |
dc.contributor.author | Coughlan, Lynda | |
dc.contributor.author | Bukreyev, Alexander | |
dc.contributor.author | van der Werf, Sylvie | |
dc.contributor.author | Guedj, Jérémie | |
dc.contributor.author | Sanders, Rogier W | |
dc.contributor.author | van Gils, Marit J | |
dc.contributor.author | Le Grand, Roger | |
dc.date.accessioned | 2021-10-28T18:11:34Z | |
dc.date.available | 2021-10-28T18:11:34Z | |
dc.date.issued | 2021-10-20 | |
dc.identifier.uri | http://hdl.handle.net/10713/17005 | |
dc.description.abstract | Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation. | en_US |
dc.description.uri | https://doi.org/10.1038/s41467-021-26354-0 | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.ispartof | Nature Communications | en_US |
dc.rights | © 2021. The Author(s). | en_US |
dc.title | COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1038/s41467-021-26354-0 | |
dc.identifier.pmid | 34671037 | |
dc.source.volume | 12 | |
dc.source.issue | 1 | |
dc.source.beginpage | 6097 | |
dc.source.endpage | ||
dc.source.country | England |